CALGARY,
AB and MOUNTAIN VIEW,
Calif., March 22, 2023 /CNW/ - WILLOW BIOSCIENCES,
(TSX: WLLW) (OTCQB: CANSF) and SUANFARMA today jointly announced
that they have, together with SUANFARMA's CIPAN manufacturing site,
completed the development and manufacturing process in pilot scale
for the WILLOW-owned ingredient, Cannabigerol (CBG). The
36 m3 scaling-up
production batches required for the forthcoming qualification and
registration will be completed during 2023.
- SUANFARMA' s CIPAN manufacturing site has significant expertise
as a CDMO in fermentation and purification technologies under the
highest standards of quality.
- WILLOW BIOSCIENCES is a leading biotechnology company focused
on revolutionizing industrial manufacturing of pure, consistent and
sustainable functional ingredients using its
FutureGrown™ platform.
- WILLOW'S CBG, the company's first functional ingredient for
consumer care and health & wellness applications, is clinically
tested to be safe and has been shown to act as a potent
antioxidant, anti-inflammatory and anti-microbial.
After this successful technology transfer, development, and
piloting, SUANFARMA and WILLOW BIOSCIENCES plan to broaden the
relationship by offering an end-to-end synthetic biology solution
and expanding their joint product portfolio. With this alliance,
both companies will bring together their existing pharma and
biotech capabilities for the production of ingredients, including
anti-infectives and other Active Pharmaceutical Ingredients (APIs)
and intermediates for Pharma and natural ingredients designed for
the Health & Wellness and Food & Beverage industries.
"CIPAN has proven itself a highly capable manufacturing
partner with the efficient scaling and production of our first
ingredient, CBG. We are excited to broaden the collaboration
further to both offer an end-to-end solution to our customers while
also expanding the portfolio of products with
SUANFARMA" says Chris
Savile, COO of Willow Biosciences.
"The development and piloting of this USP/DSP process in
collaboration with Willow Biosciences is now completed and
constitutes a very important milestone towards a robust, reliable,
and efficient manufacturing process at industrial scale. This
collaboration opens new business opportunities for both companies
with important synergies." says Daniel Rivero, Industrial Director of
Suanfarma.
About WILLOW BIOSCIENCES
Willow develops and produces precision fermented functional
ingredients for the health and wellness, food and beverage and
personal care markets. Willow's
FutureGrown™ biotechnology platform allows
large-scale production with sustainability at its core. Willow's
R&D team has a proven track record of developing and
commercializing bio-based manufacturing processes and products to
benefit our B2B partners and their customers. For more information,
visit www.willowbio.com.
About SUANFARMA
SUANFARMA founded in 1993, is a B2B life science partner
specialized in the development, production, and commercialization
of ingredients for the pharmaceutical, veterinary and nutraceutical
industries.
All facilities comply with the highest existing regulations in
the pharmaceutical industry. With the support of a consolidated and
strong commercial network with 12 local offices placed
strategically around the world, SUANFARMA provides its services to
more than 3,000 active customers in over 70 countries. More
information: www.suanfarma.com
FutureGrown™ is a registered trademark of Willow
Biosciences Inc. All other trademarks are trademarks of their
respective holders.
Forward-Looking
Statements
This news release may include forward-looking statements
including opinions, assumptions, estimates and the assessment of
future plans and operations of the companies, and, more
particularly, statements concerning: intentions to broaden the
relationship between the two companies by offering an end-to-end
synthetic biology solution and expanding their joint product
portfolio and scaling production batches of CBG; and the business
plan of the companies, generally. When used in this news release,
the words "will," "anticipate," "believe," "estimate," "expect,"
"intent," "may," "project," "should," and similar expressions are
intended to be among the statements that identify forward-looking
statements. The forward-looking statements are founded on the basis
of expectations and assumptions made by the companies which
include, but are not limited to: the success of strategic
partnerships; the market for CBG products; the ability to obtain
and retain applicable licences; the ability to obtain suitable
manufacturing partners and other strategic relationships; and the
successful implementation of the companies' commercialization and
production strategy, generally. Forward-looking statements are
subject to a wide range of risks and uncertainties, and although
the companies believe that the expectations represented by such
forward-looking statements are reasonable, there can be no
assurance that such expectations will be realized. Any number of
important factors could cause actual results biotechnology industry
in general; the success of research and development strategies;
infringement on intellectual property; failure to benefit from
partnerships or successfully integrate acquisitions; actions and
initiatives of federal, state and provincial governments and
changes to government policies and the execution and impact of
these actions, initiatives and policies; import/export and research
restrictions for operations; the size of the CBG market;
competition from other industry participants; adverse U.S.,
Canadian and global economic conditions; adverse global events and
public-health crises, including the evolving COVID-19 outbreak;
failure to comply with certain regulations; departure of key
management personnel or inability to attract and retain talent; and
other factors more fully described from time to time in the reports
and filings made by Willow with securities regulatory authorities.
Please refer to Willow's most recent annual information form and
management's discussion and analysis for additional risk factors
relating to Willow, which can be accessed either on Willow's
website at www.willowbio.com or under Willow's profile on
www.sedar.com.
The forward-looking statements contained in this news release
are made as of the date hereof and the companies do not undertake
any obligation to update publicly or to revise any of the included
forward-looking statements, except as required by applicable law.
The forward-looking statements contained herein are expressly
qualified by this cautionary statement.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/willow--suanfarma-announce-completed-development-and-manufacturing-process-for-cbg-and-commitment-to-the-production-of-new-molecules-in-a-natural-way-301778088.html
SOURCE Willow Biosciences Inc.